Understanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM)

Am J Med Genet A. 2024 Jun;194(6):e63541. doi: 10.1002/ajmg.a.63541. Epub 2024 Jan 17.

Abstract

Neurofibromatosis Type 1 (NF1) is an autosomal dominant genetic disorder that can cause an individual significant chronic pain (CP). CP affects quality of life and daily functioning, yet there are limited effective treatments for CP within NF1. The current study describes the impact of CP using the Neurofibromatosis Pain Module (NFPM). The NFPM is a self-reported clinical assessment that evaluates the impact of CP across multiple domains (e.g., interference, severity, tolerance, and symptomology) and three prioritized pain regions. A cross-sectional study (N = 242) asked adults with NF1 to describe and rate their pain using the NFPM. The results indicated that they reported moderate pain severity (M = 6.6, SD = 2.0) on a 0-10 scale, that 54% (n = 131) had been in pain at least 24 days in the last 30, for 75% (n = 181) sleep was affected, and 16% reported that nothing was effective in reducing their CP for their primary pain region. The current results extend previously published work on CP within adults with NF1 and indicate that more emphasis on understanding and ameliorating CP is required. The NFPM is a sensitive clinical measure that provides qualitative and quantitative responses to inform medical providers about changes in CP.

Keywords: Neurofibromatosis Type 1; chronic pain; clinical measurement; pain interference; pain severity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Chronic Pain* / genetics
  • Cross-Sectional Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neurofibromatosis 1* / complications
  • Neurofibromatosis 1* / genetics
  • Pain Measurement*
  • Quality of Life*
  • Self Report
  • Surveys and Questionnaires
  • Young Adult